

FOR IMMEDIATE RELEASE

Microvention Raises \$10 Million in Late-Stage Financing

*Over 600 Patients Treated for Cerebral Vascular Diseases
Using Company's HydroCoil Embolic System Technology*

ALISO VIEJO, CA Sept. 4, 2003 -- Microvention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral vascular diseases, announced today it recently closed a \$10 million round of Series D venture funding. The capital raised brings total financing in Microvention to approximately \$53 million. This funding allows Microvention to accelerate its sales, marketing and development initiatives in support of its increasingly adopted endovascular aneurysm products.

Participants in this latest round of funding include Crosspoint Venture Partners, Advanced Technology Ventures, De Novo Ventures, Delphi Ventures, Asset Management Partners, U.S. Venture Partners and A.G. Edwards Capital.

“This financing provides the necessary working capital to fuel the continued growth of Microvention,” said Michael Kleine, President and CEO, Microvention. “We are very pleased our investors support our vision through their investment and participation in the company.”

Microvention also announced that approximately 600 patients have been treated with its HydroCoil Embolic System (HES), including over 100 patients in its HEAL (HydroCoil for Endovascular Aneurysm occlusion) post-market clinical study, which examines the performance of HES in the treatment of cerebral aneurysms. “Early indications show great promise with our embolic system's ability to more completely fill and promote healing in aneurysms,” Kleine said. “We look forward to publishing initial follow-up data upon completion of the first phase of the HEAL study in early 2004.”

Kleine further noted, “The growing adoption of our next-generation technology by the medical community demonstrates this advanced treatment is a viable and frequently preferable treatment option compared to traditional surgical approaches and existing endovascular coil embolization technology.”

“Our clinical experience with Microvention's HES has been exceptional,” said Dr. Jacques Dion of Emory University Hospital. “Aside from increased filling of the aneurysm that can decrease the potential for coil compaction, there is the potential of a pronounced healing response similar to that demonstrated in preclinical studies. The combination of these two attributes, which do not exist with conventional coil embolization technologies, clearly places the HES as a promising new technology for the treatment of cerebral aneurysms.”

“We are seeing rapid growth and changes in the cerebral aneurysm market,” said Kleine. “New and improved technology, such as the HydroCoil Embolic System, coming on the heels of the International Subarachnoid Aneurysm Trial (ISAT), provides the tools and the clinical data to support increased endovascular treatment. The ISAT data, published in *The Lancet* in October 2002, showed the benefits of endovascular treatment compared to open surgery. Slowing adoption of endovascular treatment has been the lack of an embolic technology that can provide better healing and a more durable treatment. HydroCoil is designed to be a significant advance in both areas.”

A cerebral aneurysm is a ballooning of a weakened region of a blood vessel. If left untreated, the aneurysm may continue to weaken until it ruptures and bleeds into the brain. Approximately 2 to 5 percent of the U.S. population has cerebral aneurysms, most of which go undetected. Each year approximately 150,000 patients worldwide are treated for cerebral aneurysms, of which 25 percent are treated by endovascular coil embolization rather than traditional surgical approaches. Industry experts believe up to 75 percent of patients currently treated for cerebral aneurysms could be treated with endovascular devices, indicating a near-term market potential for such devices of approximately \$500 million. Endovascular embolization is one of the most rapidly growing vascular markets for medical technology. Microvention sells its products through its direct sales force in the U.S., France, Germany and the United Kingdom and through distributors in various other countries.

About Microvention, Inc.

Microvention, Inc. (www.microvention.com) is a privately held medical-device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System, its next-generation endovascular coil system designed to treat cerebral aneurysms.

Microvention Contacts:

Michael Kleine, President, CEO
William Hughes, Vice President, CFO
Ph. 949-768-1184
Fx. 949-768-0464